Two Takeda Diabetes Drug Applications, FDA Asks For More Info

Takeda says it has received a complete response letter from the FDA regarding NDAs (new drug applications) for alogliptin and fixed-dose combination alogliptin and pioglitazone - both diabetes type 2 investigational therapies. Takeda says it has recently been providing the FDA (Food and Drug Administration) with postmarketing data from markets outside the USA. Takeda believes it can provide the ...